UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

January 12, 2010

 

Commission File Number:0001284823

 


 

XYRATEX LTD

(Translation of registrant’s name into English)

 

Langstone Road,

Havant

PO9 1SA

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or 40-F.

Form 20-F   x      Form 40-F    o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)   o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)   o

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to rule 12g3-2(b) under the Securities Exchange Act of 1934.  Yes   o      No   x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-                  

 

 

 



 

FOR IMMEDIATE RELEASE

 

Xyratex Ltd Announces Results for the Fourth Quarter and Fiscal Year 2009

 

Havant, UK, January 12, 2010—Xyratex Ltd. (Nasdaq: XRTX), a leading provider of enterprise class data storage subsystems and storage process technology, today announced results for the fourth quarter and fiscal year ended November 30, 2009.  Revenues for the fourth quarter were $243.0 million, a decrease of 14.9% compared to revenues of $285.4 million for the same period last year.

 

For the fourth quarter, GAAP net income was $1.6 million, or $0.05 per diluted share compared to a GAAP net loss of $55.7 million in the same period last year. Non-GAAP net income increased to $7.9 million, or a diluted earnings per share of $0.26, compared to non-GAAP net income of $0.4 million, or $0.02 per diluted share, in the same quarter a year ago(1).

 

Gross profit margin in the fourth quarter was 15.6%, compared to 12.5% in the same period last year and 16.7% in the prior quarter.

 

Revenues from sales of our Networked Storage Solutions (NSS) products were $203.4 million in the fourth quarter as compared to $222.3 million in the same quarter a year ago, a decrease of 8.5%. Gross profit margin in the Networked Storage Solutions business was 13.2% as compared to 8.4% a year ago. Revenues from sales of our Storage Infrastructure (SI) products were $39.5 million as compared to $63.1 million in the same quarter a year ago, a decrease of 37.4%. Gross profit margin in the Storage Infrastructure business was 28.7% as compared to 27.3% a year ago.

 

Revenues for fiscal year 2009 were $867.9 million, a decrease of 17.3%, compared to revenues of $1,049.7 million for fiscal year 2008. Revenues from sales of our NSS products were $762.0 million for the year as compared to $855.8 in 2008, a decrease of 11.0%. Revenues from sales of our SI products were $105.9 million as compared to $193.9 million in 2008, a decrease of 45.4%.

 

GAAP net loss for fiscal year 2009 was $16.4 million or $0.56 per diluted share compared to a GAAP net loss of $47.9 million for fiscal year 2008. Non-GAAP net income for fiscal year 2009 decreased to $1.5 million, or a diluted earnings per share of $0.05, compared to non-GAAP net income of $16.2 million, or $0.54 per diluted share, for fiscal year 2008.

 



 

When comparing with the prior year it should be noted that the 2008 fourth quarter and full year results included some significant non-recurring charges related to the deterioration in the macroeconomic climate in that quarter. GAAP net loss and non-GAAP net income included additional inventory and vendor claim provisions totaling approximately $7 million. These charges reduced the NSS gross profit margin in the fourth quarter of fiscal 2008 by 3.2%. GAAP net loss also included non-cash charges totaling approximately $54 million, being an impairment of goodwill and a valuation allowance against the deferred tax asset.

 

“Although our Fiscal Year 2009 proved to be very challenging, I believe we delivered a good overall performance through reducing our cost base and supporting our customers’ changing needs. The results of the fourth quarter reflect the component supply issues, primarily related to semi conductors, that we have been working to address, which have constrained our NSS shipment capability through the second half of the year. I continue to be encouraged with the demand environment we are seeing for 2010 and believe that component supply will improve from the actions we are taking,” said Steve Barber, CEO of Xyratex. “We are confident that the fundamentals within the markets we serve are improving and that our technology and strong execution will benefit us over the longer term.”

 

Business Outlook

 

The following statements are based on current expectations. These statements are forward-looking, and actual results may differ materially. They reflect a significant improvement in the outlook for the SI business including customer forecasts of approximately $140 million for delivery in the first half of 2010.

 

·                  Revenue in the first quarter of 2010 is projected to be in the range $245 to $285 million.

·                  Fully diluted earnings per share is anticipated to be between $0.24 and $0.52 on a GAAP basis in the first quarter. On a non-GAAP basis fully diluted earnings per share is anticipated to be between $0.32 and $0.60. Non-GAAP earnings per share excludes amortization of intangible assets, equity compensation expense, specified non-recurring items and related taxation expense.

 



 

Conference Call/Webcast Information

 

The company will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET on Tuesday, January 12, 2010.

 

The conference call can be accessed online via the company’s website www.xyratex.com/investors, or by telephone as follows:

 

United States

(866) 272-9941

Outside the United States

(617) 213-8895

Passcode

66286501

 

A replay will be available via the company’s website www.xyratex.com/investors, or can be accessed by telephone through January 19, 2010 as follows:

 

United States

(888) 286-8010

Outside the United States

(617) 801-6888

Passcode

33869460

 



 


(1) Non-GAAP net income (loss) and diluted earnings (loss) per share excludes (a) amortization of intangible assets, (b) equity compensation expense, (c) specified non-recurring items, such as restructuring costs, the impairment of goodwill and valuation allowance against a deferred tax asset, (d) the related tax effects and (e) the effect of changes in exchange rates on the income tax expense. Reconciliation of non-GAAP net income (loss) and diluted earnings (loss) per share to GAAP net income (loss) and GAAP diluted earnings (loss) per share is included in a table immediately following the condensed consolidated statements of cash flow below.

 

The intention in providing these non-GAAP measures is to provide supplemental information regarding the Company’s operational performance while recognizing that they have material limitations and that they should only be referred to with reference to the corresponding GAAP measure.

 

The Company believes that the provision of these non-GAAP financial measures is useful to investors and investment analysts because it enables comparison to the Company’s historical operating results, those of competitors and other industry participants and also provides transparency to the measures used by management in operational and financial decision making. In relation to the specific items excluded: (a) intangible assets represent costs incurred by the acquired business prior to acquisition, are not cash costs and will not be replaced when the assets are fully amortized and therefore the exclusion of these costs provides management and investors with better visibility of the costs required to generate revenue over time; (b) equity compensation expense is non-cash in nature and is outside the control of management during the period in which the expense is incurred; (c) restructuring costs are not comparable across periods or with other companies and the impairment of goodwill and the valuation allowance against the deferred tax asset are non-recurring,  non-cash and are not comparable across periods or with other companies; (d) the exclusion of the related tax effects of excluding items (a) to (c) is necessary to show the effect on net income of the change in tax expense that would have been recorded if these items had not been incurred; (e) the effect of changes in exchange rates on deferred tax balances is non-cash and is not comparable across periods or with other companies.

 



 

Safe Harbor Statement

 

This press release contains forward—looking statements. These statements relate to future events or our future financial performance, including our projected revenue and fully diluted earnings per share data (on a GAAP and non-GAAP basis) for the first quarter. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Factors that might cause such a difference include our inability to compete successfully in the competitive and rapidly changing marketplace in which we operate, failure to retain key employees, changes in our customers volume requirements, cancellation or delay of projects and adverse general economic conditions in the United States and internationally. These risks and other factors include those listed under “Risk Factors” and elsewhere in our Annual Report on Form 20-F as filed with the Securities and Exchange Commission (File No. 000-50799). In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

About Xyratex

 

Xyratex is a leading provider of enterprise class data storage subsystems and storage process technology. The company designs and manufactures enabling technology that provides OEM and disk drive manufacturers with data storage products to support high-performance storage and data communication networks. Xyratex has over 25 years of experience in research and development relating to disk drives, storage systems and high-speed communication protocols.

 

Founded in 1994 in an MBO from IBM, and with headquarters in the UK, Xyratex has an established global base with R&D and operational facilities in Europe, the United States and South East Asia.

 

For more information, visit www.xyratex.com.

 

Contact:

 

Xyratex Investor Relations

Brad Driver, +1 510 687-5260

Email: bdriver@us.xyratex.com

Website: www.xyratex.com

 


 


 

XYRATEX LTD

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

Three Months Ended,

 

Year Ended

 

 

 

November 30,

 

November 30,

 

November 30,

 

November 30,

 

 

 

2009

 

2008

 

2009

 

2008

 

 

 

(US dollars in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

Revenues:

 

 

 

 

 

 

 

 

 

Networked Storage Solutions

 

$

203,439

 

$

222,300

 

$

762,028

 

$

855,770

 

Storage Infrastructure

 

39,534

 

63,127

 

105,863

 

193,946

 

Total revenues

 

242,973

 

285,427

 

867,891

 

1,049,716

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

205,014

 

249,827

 

742,615

 

891,139

 

Gross profit:

 

 

 

 

 

 

 

 

 

Networked Storage Solutions

 

26,874

 

18,643

 

97,981

 

107,275

 

Storage Infrastructure

 

11,348

 

17,234

 

28,202

 

52,566

 

Equity compensation

 

(263

)

(277

)

(907

)

(1,264

)

Total gross profit

 

37,959

 

35,600

 

125,276

 

158,577

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

17,560

 

22,726

 

71,062

 

85,897

 

Selling, general and administrative

 

13,538

 

15,984

 

56,463

 

63,686

 

Amortization of intangible assets

 

951

 

1,223

 

3,939

 

4,882

 

Impairment of goodwill

 

 

34,256

 

 

34,256

 

Restructuring costs

 

1,170

 

 

5,898

 

 

Total operating expenses

 

33,219

 

74,189

 

137,362

 

188,721

 

Operating income (loss)

 

4,740

 

(38,589

)

(12,086

)

(30,144

)

Interest income, net

 

4

 

166

 

114

 

1,618

 

Income (loss) before income taxes

 

4,744

 

(38,423

)

(11,972

)

(28,526

)

Provision for income taxes

 

3,194

 

17,324

 

4,442

 

19,383

 

Net income (loss)

 

$

1,550

 

$

(55,747

)

$

(16,414

)

$

(47,909

)

 

 

 

 

 

 

 

 

 

 

Net earnings (loss) per share:

 

 

 

 

 

 

 

 

 

Basic

 

$

0.05

 

$

(1.92

)

$

(0.56

)

$

(1.64

)

Diluted

 

$

0.05

 

$

(1.92

)

$

(0.56

)

$

(1.64

)

 

 

 

 

 

 

 

 

 

 

Weighted average common shares (in thousands), used in

 

 

 

 

 

 

 

 

 

computing net earnings (loss) per share:

 

 

 

 

 

 

 

 

 

Basic

 

29,462

 

29,096

 

29,402

 

29,157

 

Diluted

 

30,588

 

29,096

 

29,402

 

29,157

 

 



 

XYRATEX LTD

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

November 30,

 

November 30,

 

 

 

2009

 

2008

 

 

 

(US dollars and amounts in
thousands)

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

51,935

 

$

28,013

 

Accounts receivable, net

 

124,715

 

140,879

 

Inventories

 

108,625

 

128,183

 

Prepaid expenses

 

4,784

 

2,746

 

Deferred income taxes

 

405

 

1,000

 

Other current assets

 

5,825

 

4,430

 

Total current assets

 

296,289

 

305,251

 

Property, plant and equipment, net

 

44,485

 

47,229

 

Intangible assets, net

 

7,207

 

11,162

 

Deferred income taxes

 

6,269

 

9,545

 

Total assets

 

$

354,250

 

$

373,187

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

96,386

 

$

111,295

 

Employee compensation and benefits payable

 

8,580

 

9,745

 

Deferred revenue

 

10,620

 

8,386

 

Income taxes payable

 

2,013

 

2,573

 

Foreign currency contracts

 

 

13,266

 

Other accrued liabilities

 

17,413

 

14,333

 

Total current liabilities

 

135,012

 

159,598

 

Long-term debt

 

 

 

Total liabilities

 

135,012

 

159,598

 

 

 

 

 

 

 

Shareholders’ equity

 

 

 

 

 

Common shares (in thousands), par value $0.01 per share 70,000 authorized, 29,461 and 29,146 issued and outstanding

 

294

 

291

 

Additional paid-in capital

 

370,926

 

366,067

 

Accumulated other comprehensive income (loss)

 

3,598

 

(13,603

)

Accumulated deficit

 

(155,580

)

(139,166

)

Total shareholders’ equity

 

219,238

 

213,589

 

Total liabilities and shareholders’ equity

 

$

354,250

 

$

373,187

 

 



 

XYRATEX LTD

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

Year Ended,

 

 

 

November 30,

 

November 30,

 

 

 

2009

 

2008

 

 

 

(US dollars in thousands)

 

Cash flows from operating activities:

 

 

 

 

 

Net income (loss)

 

$

(16,414

)

$

(47,909

)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

 

 

 

 

 

Depreciation

 

18,197

 

15,770

 

Amortization of intangible assets

 

3,939

 

4,882

 

Impairment of intangible assets

 

 

34,256

 

Non-cash equity compensation

 

5,625

 

7,646

 

Loss on sale of assets

 

 

185

 

Changes in assets and liabilities, net of impact of acquisitions and divestitures

 

 

 

 

 

Accounts receivable

 

16,164

 

(18,552

)

Inventories

 

19,558

 

(36,521

)

Prepaid expenses and other current assets

 

165

 

1,455

 

Accounts payable

 

(14,909

)

15,249

 

Employee compensation and benefits payable

 

(1,165

)

(3,535

)

Deferred revenue

 

2,234

 

(6,826

)

Income taxes payable

 

(560

)

1,408

 

Deferred income taxes

 

3,021

 

16,944

 

Other accrued liabilities

 

3,433

 

2,718

 

Net cash provided by (used in) operating activities

 

39,288

 

(12,830

)

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Investments in property, plant and equipment

 

(15,453

)

(25,763

)

Net cash used in investing activities

 

(15,453

)

(25,763

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Repurchases of common shares

 

 

(6,116

)

Proceeds from issuance of shares

 

87

 

2,044

 

Net cash provided by (used in) financing activities

 

87

 

(4,072

)

Change in cash and cash equivalents

 

23,922

 

(42,665

)

Cash and cash equivalents at beginning of period

 

28,013

 

70,678

 

Cash and cash equivalents at end of period

 

$

51,935

 

$

28,013

 

 



 

XYRATEX LTD

SUPPLEMENTAL INFORMATION

 

 

 

Three Months Ended

 

Year Ended

 

 

 

November 30,

 

November 30,

 

November 30,

 

November 30,

 

 

 

2009

 

2008

 

2009

 

2008

 

 

 

(US dollars in thousands, except per
share amounts)

 

(US dollars in thousands, except
per share amounts)

 

Summary Reconciliation Of GAAP Net Income (Loss) To Non-GAAP Net Income (Loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net income (loss)

 

$

1,550

 

$

(55,747

)

$

(16,414

)

$

(47,909

)

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

951

 

1,223

 

3,939

 

4,882

 

Impairment of goodwill

 

 

34,256

 

 

34,256

 

Equity compensation

 

1,758

 

1,755

 

5,625

 

7,646

 

Restructuring costs

 

1,170

 

 

5,898

 

 

Tax effect of impairment of goodwill

 

 

(9,592

)

 

(9,592

)

Tax effect of other non-GAAP adjustments

 

2,460

 

(1,024

)

2,460

 

(3,791

)

Valuation allowance against UK deferred tax asset

 

 

29,466

 

 

29,466

 

Effect on deferred tax of changes to UK tax rates and exchange rates

 

 

110

 

 

1,254

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP net income

 

$

7,889

 

$

447

 

$

1,508

 

$

16,212

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Summary Reconciliation Of Diluted GAAP Earnings (Loss) Per Share To Diluted Non-GAAP Earnings (Loss) Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted GAAP earnings (loss) per share

 

$

0.05

 

$

(1.92

)

$

(0.56

)

$

(1.64

)

 

 

 

 

 

 

 

 

 

 

Amortization of intangible assets

 

0.03

 

0.04

 

0.13

 

0.17

 

Impairment of goodwill

 

 

1.18

 

 

1.17

 

Equity compensation

 

0.06

 

0.06

 

0.19

 

0.26

 

Restructuring costs

 

0.04

 

 

0.20

 

 

Tax effect of impairment of goodwill

 

 

(0.33

)

 

(0.33

)

Tax effect of other non-GAAP adjustments

 

0.08

 

(0.04

)

0.08

 

(0.13

)

Valuation allowance against UK deferred tax asset

 

 

1.01

 

 

1.00

 

Effect on deferred tax of changes to UK tax rates and exchange rates

 

 

0.00

 

 

0.04

 

 

 

 

 

 

 

 

 

 

 

Diluted non-GAAP earnings per share

 

$

0.26

 

$

0.02

 

$

0.05

 

$

0.54

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Summary Of Equity Compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

263

 

277

 

907

 

1,264

 

Research and development

 

571

 

567

 

1,856

 

2,469

 

Selling, general and administrative

 

924

 

911

 

2,862

 

3,913

 

 

 

 

 

 

 

 

 

 

 

Total equity compensation

 

1,758

 

1,755

 

5,625

 

7,646

 

 



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

XYRATEX LTD

 

 

 

(Registrant)

 

 

 

 

 

 

 

 

Date: January 12, 2010

 

By:

/s/ Richard Pearce

 

 

 

Name: Richard Pearce

 

 

 

Title: Chief Financial Officer